IDIOPATHIC INFLAMMATORY MYOPATHIES (IIMS)
Clinical trials for IDIOPATHIC INFLAMMATORY MYOPATHIES (IIMS) explained in plain language.
Never miss a new study
Get alerted when new IDIOPATHIC INFLAMMATORY MYOPATHIES (IIMS) trials appear
Sign up with your email to follow new studies for IDIOPATHIC INFLAMMATORY MYOPATHIES (IIMS), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Could a dengue vaccine be safe for autoimmune patients? new trial seeks answers
⭐️ VACCINE ⭐️ Recruiting nowThis study is testing a live attenuated dengue vaccine (Butantan-DV) in people aged 12–59 with autoimmune rheumatic diseases (like rheumatoid arthritis or lupus) who are stable and on low or no immune-suppressing drugs. Researchers want to see if the vaccine triggers a good immun…
Matched conditions: IDIOPATHIC INFLAMMATORY MYOPATHIES (IIMS)
Phase: PHASE4 • Sponsor: University of Sao Paulo General Hospital • Aim: ⭐️ VACCINE ⭐️
Last updated May 13, 2026 15:58 UTC
-
New hope for rare muscle disease: drug shows promise in early trial
Disease control Recruiting nowThis study is testing a daily pill called deucravacitinib in 10 adults with active inflammatory muscle diseases (myositis) that haven't responded well to standard treatments. The goal is to see if the drug can reduce muscle inflammation and improve strength and daily function ove…
Matched conditions: IDIOPATHIC INFLAMMATORY MYOPATHIES (IIMS)
Sponsor: Peking University People's Hospital • Aim: Disease control
Last updated May 14, 2026 12:05 UTC
-
Immune cell combo tackles tough autoimmune conditions
Disease control Recruiting nowThis study tests a new treatment for people with certain autoimmune diseases (rheumatoid arthritis, Sjögren's disease, myositis, and scleroderma) that have not responded to standard therapies. The treatment combines AlloNK, a type of immune cell from donated cord blood, with ritu…
Matched conditions: IDIOPATHIC INFLAMMATORY MYOPATHIES (IIMS)
Phase: PHASE2 • Sponsor: Artiva Biotherapeutics, Inc. • Aim: Disease control
Last updated May 11, 2026 20:51 UTC